290 related articles for article (PubMed ID: 16970054)
1. Increased plasma homocysteine and allantoin levels in coronary artery disease: possible link between homocysteine and uric acid oxidation.
Ozkan Y; Yardim-Akaydin S; Imren E; Torun M; Simşek B
Acta Cardiol; 2006 Aug; 61(4):432-9. PubMed ID: 16970054
[TBL] [Abstract][Full Text] [Related]
2. Adenosine plasma level correlates with homocysteine and uric acid concentrations in patients with coronary artery disease.
Fromonot J; Deharo P; Bruzzese L; Cuisset T; Quilici J; Bonatti S; Fenouillet E; Mottola G; Ruf J; Guieu R
Can J Physiol Pharmacol; 2016 Mar; 94(3):272-7. PubMed ID: 26762617
[TBL] [Abstract][Full Text] [Related]
3. Serum allantoin and aminothiols as biomarkers of chronic heart failure.
Caussé E; Fournier P; Roncalli J; Salvayre R; Galinier M
Acta Cardiol; 2017 Aug; 72(4):397-403. PubMed ID: 28705092
[TBL] [Abstract][Full Text] [Related]
4. Oxidation of uric acid in rheumatoid arthritis: is allantoin a marker of oxidative stress?
Yardim-Akaydin S; Sepici A; Ozkan Y; Torun M; Simşek B; Sepici V
Free Radic Res; 2004 Jun; 38(6):623-8. PubMed ID: 15346653
[TBL] [Abstract][Full Text] [Related]
5. The C677T mutation in methylenetetrahydrofolate reductase gene, plasma homocysteine concentration and the risk of coronary artery disease.
Kadziela J; Janas J; Dzielińska Z; Szperl M; Gaździk D; Chotkowska E; Piotrowski W; Ruzyłło W
Kardiol Pol; 2003 Jul; 59(7):17-26; discussion 26. PubMed ID: 14560345
[TBL] [Abstract][Full Text] [Related]
6. Effects of folic acid and N-acetylcysteine on plasma homocysteine levels and endothelial function in patients with coronary artery disease.
Yilmaz H; Sahin S; Sayar N; Tangurek B; Yilmaz M; Nurkalem Z; Onturk E; Cakmak N; Bolca O
Acta Cardiol; 2007 Dec; 62(6):579-85. PubMed ID: 18214123
[TBL] [Abstract][Full Text] [Related]
7. Urate oxidation during percutaneous transluminal coronary angioplasty and thrombolysis in patients with coronary artery disease.
Yardim-Akaydin S; Kesimer M; Imren E; Sepici A; Simşek B; Torun M
Clin Chim Acta; 2005 Dec; 362(1-2):131-7. PubMed ID: 15992789
[TBL] [Abstract][Full Text] [Related]
8. Uric acid and allantoin levels in Down syndrome: antioxidant and oxidative stress mechanisms?
Zitnanová I; Korytár P; Aruoma OI; Sustrová M; Garaiová I; Muchová J; Kalnovicová T; Pueschel S; Duracková Z
Clin Chim Acta; 2004 Mar; 341(1-2):139-46. PubMed ID: 14967170
[TBL] [Abstract][Full Text] [Related]
9. A monitoring of allantoin, uric acid, and malondialdehyde levels in plasma and erythrocytes after ten minutes of running activity.
Kanďár R; Štramová X; Drábková P; Křenková J
Physiol Res; 2014; 63(6):753-62. PubMed ID: 25157658
[TBL] [Abstract][Full Text] [Related]
10. Allantoin as a marker of oxidative stress in human erythrocytes.
Kand'ár R; Záková P
Clin Chem Lab Med; 2008; 46(9):1270-4. PubMed ID: 18636793
[TBL] [Abstract][Full Text] [Related]
11. Plasma homocysteine levels in patients with isolated coronary artery ectasia.
Turhan H; Erbay AR; Yasar AS; Bicer A; Sahin O; Basar N; Yetkin E
Int J Cardiol; 2005 Sep; 104(2):158-62. PubMed ID: 16168808
[TBL] [Abstract][Full Text] [Related]
12. Association between serum uric acid level and the severity of coronary artery disease in patients with obstructive coronary artery disease.
Yu J; Han J; Mao J; Guo L; Gao W
Chin Med J (Engl); 2014; 127(6):1039-45. PubMed ID: 24622431
[TBL] [Abstract][Full Text] [Related]
13. The relationship between uric acid and its oxidative product allantoin: a potential indicator for the evaluation of oxidative stress in birds.
Tsahar E; Arad Z; Izhaki I; Guglielmo CG
J Comp Physiol B; 2006 Sep; 176(7):653-61. PubMed ID: 16705445
[TBL] [Abstract][Full Text] [Related]
14. Aminothiols and allantoin in chronic dialysis patients: effects of hemodialysis sessions.
Caussé E; Ribes D; Longlune N; Kamar N; Durand D; Salvayre R; Rostaing L
Clin Nephrol; 2010 Jan; 73(1):51-7. PubMed ID: 20040352
[TBL] [Abstract][Full Text] [Related]
15. Hyperhomocysteinemia measured by immunoassay: a valid measure of coronary artery atherosclerosis.
Stauffenberg MT; Lange RA; Hillis LD; Cigarroa J; Hsu RM; Devaraj S; Jialal I
Arch Pathol Lab Med; 2004 Nov; 128(11):1263-6. PubMed ID: 15504061
[TBL] [Abstract][Full Text] [Related]
16. Related factors of serum uric acid in patients with primary hypertension and hyperhomocysteinemia.
Wang B; Lin L; Zhao C
Clin Exp Hypertens; 2016; 38(3):312-6. PubMed ID: 27028508
[TBL] [Abstract][Full Text] [Related]
17. Influence of methionine synthase (A2756G) and methionine synthase reductase (A66G) polymorphisms on plasma homocysteine levels and relation to risk of coronary artery disease.
Laraqui A; Allami A; Carrié A; Coiffard AS; Benkouka F; Benjouad A; Bendriss A; Kadiri N; Bennouar N; Benomar A; Guedira A; Raisonnier A; Fellati S; Srairi JE; Benomar M
Acta Cardiol; 2006 Feb; 61(1):51-61. PubMed ID: 16485733
[TBL] [Abstract][Full Text] [Related]
18. Oxidation products of uric acid and ascorbic acid in preterm infants with chronic lung disease.
Ogihara T; Kim HS; Hirano K; Imanishi M; Ogihara H; Tamai H; Okamoto R; Mino M
Biol Neonate; 1998; 73(1):24-33. PubMed ID: 9458939
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of allantoin levels as a new marker of oxidative stress in Behçet's disease.
Yardim-Akaydin S; Sepici A; Ozkan Y; Simşek B; Sepici V
Scand J Rheumatol; 2006; 35(1):61-4. PubMed ID: 16467045
[TBL] [Abstract][Full Text] [Related]
20. Plasma total homocysteine levels in patients with early-onset coronary heart disease and a low cardiovascular risk profile.
Donner MG; Klein GK; Mathes PB; Schwandt P; Richter WO
Metabolism; 1998 Mar; 47(3):273-9. PubMed ID: 9500562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
